CPRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Catalyst Pharmaceuticals's annualized Gross Profit for the quarter that ended in Sep. 2024 was $437.7 Mil. Catalyst Pharmaceuticals's average Total Assets over the quarter that ended in Sep. 2024 was $739.2 Mil. Therefore, Catalyst Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 59.21%.
The historical data trend for Catalyst Pharmaceuticals's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | 101.31 | 66.97 | 55.31 | 58.63 | 81.88 |
Catalyst Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Gross-Profit-to-Asset % | Get a 7-Day Free Trial | 82.62 | 85.82 | 61.60 | 63.45 | 59.21 |
For the Biotechnology subindustry, Catalyst Pharmaceuticals's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's Gross-Profit-to-Asset % falls into.
Catalyst Pharmaceuticals's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (A: Dec. 2023 ) | / | ( (Total Assets (A: Dec. 2022 ) | + | Total Assets (A: Dec. 2023 )) | / count ) |
= | 346.237 | / | ( (375.63 | + | 470.114) | / 2 ) | |
= | 346.237 | / | 422.872 | ||||
= | 81.88 % |
Catalyst Pharmaceuticals's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (Q: Sep. 2024 ) | / | ( (Total Assets (Q: Jun. 2024 ) | + | Total Assets (Q: Sep. 2024 )) | / count ) |
= | 437.672 | / | ( (706.36 | + | 772.01) | / 2 ) | |
= | 437.672 | / | 739.185 | ||||
= | 59.21 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
David S Tierney | director | C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080 |
Steve Miller | officer: VP Development & Management | 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134 |
Carmen Jeffrey Del | officer: Chief Commercial Officer | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134 |
Gary Ingenito | officer: Chief Medical Officer | 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134 |
Richard J Daly | director | 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134 |
Molly Harper | director | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134 |
Brian Elsbernd | officer: Chief Compliance/Legal Officer | 355 ALHAMBRA CIRCLE, CORAL GABLES FL 33134 |
Alicia Grande | officer: Chief Accounting Officer | 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134 |
Tamar Thompson | director | C/O AVIDITY BIOSCIENCES, INC., 10975 N. TORREY PINES RD., SUITE 150, LA JOLLA CA 92037 |
Patrick J Mcenany | director, 10 percent owner, officer: President and Chief Executive | C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742 |
Philip H Coelho | director | C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742 |
Charles B O'keeffe | director | 220 MIRACLE MILE, SUITE 234, CORAL GABLES FL 33134 |
Preethi Sundaram | officer: Chief Product Devel. Officer | 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES FL 33134 |
Donald A Denkhaus | director | 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134 |
Daniel Brennan | officer: Chief Commercial Officer | C/O INSYS THERAPEUTICS, INC, 1333 SOUTH SPECTRUM BLVD, SUITE 100, CHANDLER AZ 85286 |
From GuruFocus
By GuruFocus Research • 02-06-2024
By Marketwired • 08-20-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 03-28-2024
By GuruFocus Research • 02-06-2024
By PRNewswire • 03-19-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.